We help your bio-health project succeed
by providing you with high-value resources:
Up to 70.000 € to develop your scientific project and work on the valorization plan
Mentors to monitor and support your future project or spin-off
Networking and expert advice to generate business opportunities
Training in key areas to ensure quality improvement of your project
CaixaImpulse Programme in numbers
€1.4 million invested
3.000 hours of training
A new methodology for mutations in disease genomes
SMUFIN is a computer protocol designed for the identification of disease-causing mutations from disease genomes. This method is currently the only realistic solution for large scale and routine genomic analysis; first for research, but soon for public healthcare systems so increasingly efficient and personalised medicine may be implemented in modern societies.
New therapeutic strategy to prevent brain damage in stroke patients
ATf treatment is a new neuroprotective treatment during stroke preventing irreversible brain damage and therefore decreasing serious long-term and permanent disabilities.
Smart dressings for chronic wounds
Dermoglass wound dressing is a composite of nanoparticles embedded in nanofibers. Dermoglass targets the main cause of ulcer chronification—impaired vascularisation. Recent in vivo PoC efficacy results have shown that it is more effective than existing treatments. It promotes healthy and differentiated skin formation as well as revascularisation of the wound. Therefore it is expected to lower the risk of recurrence. Improved healing rates are expected to reduce the need for frequent medical supervision. Dermoglass dressings can be self-applied on ulcers that are in the advanced process of healing.
POC device in myocardial ischemia
The development of a device for the rapid and specific measurement of glycosylated Apo J (Apo J-Glyc) plasma levels would allow the reduction of the elapsed time between event onset and decision making, speeding up the management of patients, improving their prognosis, and reducing the associated economic costs. This project is aimed to obtain a novel sensitive and reproducible methodology for the rapid and specific quantification of ApoJ-Glyc levels as an indicator (biomarker) for the diagnosis and risk stratification of patients with myocardial ischemia previous to the irreversible degeneration or necrosis of the myocardium. This new methodology with the novel device would represent a clear medical and technical advance. The economical and social impact of the present project will be high as this device will be the first in an area for a disease that affects over 50% of the population.
Wearable device to measure human motion and posture
Werium Solutions will offer a wearable and affordable sensor, called ENLAZA, to measure human motion and posture. The startup will also offer software packages to use the sensor information in three main applications: human-computer interaction, rehabilitation of motor disorders and assessment of the therapy progress. A head-mounted human-computer interface has been specially designed for people with motor disabilities, who are unable to control computer with standard interfaces (e.g. mouse or joystick). Additionally, Werium Solutions offers a software package consisting of serious videogames to rehabilitate motor control and posture. Finally, the device can objectively measure the range of motion which allows therapists to follow the rehabilitation progress.
Intelligent monitoring system for patients and dependents
A monitoring device via phone maintains the anonymity of the person being monitored and informs caregivers about certain changes in the status of dependent persons. Examples of events that the system recognises are: the patient shows a high degree of agitation, falls, leaves the bed, room, etc. It captures audio, images, and depth maps in an area of 25 m2. This information is processed by a computer unit that is able to recognise the events related to the patient, even in dark environments thanks to the infrared sensor technology.
Protein Crystals in gels
Improving formulation and delivery of biopharmaceuticals
This pharmaceutical formulation will consist of protein nanocrystals grown in a hydrogel comprising 0.1% of a biocompatible and biodegradable peptide and 99.9% water, without the need to add other additives. These hydrogels are designed to confer stability to the protein crystals and be administered subcutaneously by injection. This pharmaceutical formulation will consist of protein nanocrystals grown in a hydrogel comprising 0.1% of a biocompatible and biodegradable peptide and 99.9% water, without the need to add other additives. These hydrogels are designed to confer stability to the protein crystals and be administered subcutaneously by injection.
New strategy to combat bacterial infections
RNRbiotics are highly active molecules with the capacity to inhibit DNA synthesis, blocking bacterial growth. This mechanism is a key factor to treat multi-resistant bacteria with a different mode of action compared to inefficient pre-existing therapies. The biofim matrix can act as a barrier to delay the diffusion of antibiotics into biofilms and also drives changes on bacterial metabolism to counterpart the antibiotic activity. Antibiotics with this key limitation include the major antibiotics used in chronic lung infections as colistin, tobramycin or ciprofloxacin. We have demonstrated the unique capacity of our molecules to inhibit bacterial biofilm formation and to destroy and eliminate preexisting bacterial biofilms, present in most infections in COPD and CF patients.
Drugs for inflammatory and cardiovascular disorders
Syntheszation of novel potent soluble Epoxide Hydrolase (sEH) inhibitors
sEH is an enzyme found within cells whose inhibition has recently shown beneficial effects in cardiovascular (hypertension, atherosclerosis, ischaemic heart disease), inflammatory (chronic obstructive pulmonary disease, renal inflammation), and metabolic diseases (diabetes type 2, metabolic syndrome) in several animal models.. We have recently synthesized a series of novel potent sEH inhibitors which clearly surpass the previously known sEH inhibitors.
Computer vision device for urologists to classificate kidney stones
myStone is designed to analyse pictures and detect the major compounds found in kidney stones as well as to provide detailed information about the stone, such as the types of components, their forms and their distribution in the stone, to allow an accurate classification and identification of it. This new product has been designed to overcome some of the handicaps detected in traditional stone analysis techniques. Compared to other techniques, myStone offers a time saving, more detailed and easy to use solution, while having the laboratory on the doctor´s desk and therewith providing autonomy for the urologist.
Kit for early Alzheimer's detection
Faster intervention on the disease progression
The project is focused in the development of a new AD early detection kit, based on the new biomarker detection in blood analysis. An increase in the percentage of the biomarker in human postmortem brains from early stages of AD compared to healthy subjects has been identified MCI is considered an early AD stage, and MCI patients appear to be at an increased risk of developing AD at the rate of 10% to 15% per year versus 1-2% in old healthy people. There may be a difference in the biomarker presence between MCI patients that do not progress to AD and those that do, in combination with other currently recognised AD risk factors. If this hypothesis is verified, we may propose a new in vitro diagnostic tool for an early AD diagnosis.
Stem cell technology
A new therapy to treat liver, lung and pandreas disease
Cell reprograming technology can turn a patient’s skin cell into stem cells to study and treat human diseases and conditions. The process involves making synthetic molecules containing genetic information that are key regulators of tissue specific stem cell i.e. neurons, heart muscle cells, eye cells, or lung cells. The tissue specific molecules containing genetic information reprograms skin cells into new stem cells that can replace damaged cells in tissues and organs. The new cell reprogramming technology developed can be used to study many diseases such as cardiac, eye, ear, and spinal cord conditions to find the cause and treatment of its symptoms. It is a world first to be able to make endoderm stem cells from patient skin cells in 7 days using a clinical grade method we have developed. Endoderm stem cells are then differentiated into lung, liver and pancreas cells.
A new potent and safe antifibrinolytic agent for the prevention and treatment of hemorrhage
Control of hemorrhage currently aims to achieve normal hemostasis, representing a delicate balance between coagulation and fibrinolysis (a normal body process that prevents blood clots from growing and causing problems). Excessive activation of the fibrinolytic system can shift the haemostatic balance leading to hemorrhagic complications. CM-352 is an optimizaed compound which do not result in thrombus formation or other unwanted side effects.
A tool for checking creatinine at home
The unique features of the device should allow the determination of creatinine outside the lab, in a doctor’s office or at a patient’s home, addressing needs of the emerging market of telemedicine. Moreover, this simple device represents a breakthrough in the methods for the determination of creatinine, since it allows the detection at very low levels with minimal interferences. Therefore, it is superior to anything that has been reported so far in this field.
A new and sensitive kit for prediction of response in metastatic colorectal cancer
PrediCTC effectively classifies responding and nonresponding mCRC patients after only one chemotherapy cycle allowing the reduction of overtreatment and the selection of a more effective therapy, with the aim of increasing patient survival as well as savings in the healthcare system. It is a noninvasive and economic clinical tool that could ameliorate the sensitivity of routine imaging methods for the evaluation of therapy response and could be used as complementary information support related to therapeutic decisions.
News & Events
September 28, 2016
BioSpain 2016 is back with with its eighth edition in Bilbao from September 28 to 30. BioSpain is the most successful biotechnology event organised by a single European country and one of the largest in the world in terms of the number of one-on-one meetings (more than 3,300).
September 14, 2016
From September 14 to 15, 2016 the premier partnering event for investors from Northern Europe in the biotechnology and medical sectors and pharmaceutical companies will take place. It is organised by the Sweden Bio and Bionordic trade associations. The conference will be held at the Waterfront Congress Center in Stockholm (Sweden).
September 13, 2016
Biopharm America, the premier event in the biotechnology sector in the United States, will be held on September 13 to 15 in Boston, the sector's benchmark cluster at the international level.